Skip to content
OpenCapital
Get started

Oruka Therapeutics, Inc. ORKA Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Revenue-—
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$4.36B+533%
Enterprise value$4.32B+690%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0×0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s indefinite-lived research and development assets?
Oruka Therapeutics, Inc. (ORKA) reported indefinite-lived research and development assets of $25.07M in Q4 2025.
What does indefinite-lived research and development assets mean?
This represents the value of acquired in-process research and development projects that are not yet subject to amortization because their useful life cannot be determined until the projects reach commercialization or are abandoned. It is a critical measure of the company's pipeline value and the capital invested in long-term growth opportunities. Changes in this balance often signal progress in clinical development or strategic shifts in the R&D portfolio.